Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: a nationwide population-based cohort study.

Sheng-Hsiang MaChun-Ying WuYing-Syuan LyuYiing-Jenq ChouYun-Ting ChangChen-Yi Wu

Published in: Clinical and experimental dermatology (2022)

SGLT2i-mediated protective effects in psoriasis could not be established. SGLT2i treatment increased psoriasis risk by 2.7-fold in patients with T2DM exhibiting renal diseases.

Keyphrases

atopic dermatitis
glycemic control
skeletal muscle